Page 1

it Immuneering Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights November 9 , 2021 Successfully completed upsized initial public offering raising $ 129.4 million in gross proceeds , providing runway into 2024 Company expects to file IND for IMM - 1-104 in Q1 2022 CAMBRIDGE , Mass . , Nov. 09 , 2021 ( GLOBE NEWSWIRE ) -- Immuneering Corporation ( Nasdaq : IMRX ) , a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics , today reported financial results for the third quarter ended September 30 , 2021 and provided recent business highlights . " We made notable progress in the third quarter , including completing our IPO , and are well - funded to support the continued development of our robust pipeline of oncology and neuroscience drug programs . In the near term , we anticipate filing our Investigational New Drug ( IND ) application for IMM - 1-104 , our dual - MEK inhibitor , targeting RAS mutant tumors , in the first quarter of 2022 , " said Ben Zeskind , Ph.D. , MBA , chief executive officer of Immuneering Corporation . Corporate Highlights • IMM - 1-104 Preclinical Data Presented at EORTC 2021 : Immuneering presented data from three posters showcasing IMM - 1-104 at the recent AACR - NCI - EORTC International Conference on Molecular Targets and Cancer Therapeutics that took place virtually from October 7-10 , 2021. The study authors concluded that IMM - 1-104 displayed broad activity across a wide range of animal tumor models with diverse RAS and RAF mutations including KRAS - G12C , KRAS - G12D , KRAS - G12S , NRAS - Q61R , and BRAF - V600E . In addition , IMM - 1-104 prompted tumor regressions similar to sotorasib in a KRAS - G12C mutant pancreatic xenograft model ( MIA PaCa - 2 ) and led to deeper durable tumor regressions in combination with sotorasib when compared to either drug alone . Transcriptomic data that was presented confirmed IMM - 1-104's deep cyclic inhibition by demonstrating strong MAPK pathway inhibition at two hours post - treatment , with a near complete release at 12 hours post - treatment . Through its short half - life , IMM - 1-104 observes an encouraging tolerability profile across animal models that may provide differentiation from FDA - approved MEK inhibitors . A replay of all three presentations can be accessed at : www.immuneering.com/publications . • Company Held Its First Key Opinion Leader Event : Immuneering held its first key opinion leader event titled “ Better Medicines for MEK , RAS and Beyond Through Signaling Dynamics " on October 12 , 2021 where participating key experts reviewed the RAS mutant tumor treatment landscape and noted the need for development of therapies outside of the KRAS - G12C mutant tumor setting . A replay of the event can be accessed at : https://ir.immuneering.com/news-events / events - presentations . • Completed Initial Public Offering : On August 3 , 2021 , Immuneering announced the closing of its upsized initial public offering of 8,625,000 shares of Class A common stock , including the full exercise by the underwriters of their overallotment option to purchase 1,125,000 shares of Class A common stock , at a public offering price of $ 15.00 per share , for total gross proceeds of approximately $ 129.4 million , before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering . • Strengthened Leadership Team and Board of Directors : Immuneering strengthened its management team with the appointment of Michael Bookman as the company's General Counsel and Secretary in July 2021. Immuneering also appointed Ann Berman to its board of directors in July 2021 . Key Development Highlights • IMM - 1-104 IND submission expected in Q1 2022 : Immuneering expects to file the IND for IMM - 1-104 in Q1 2022 and expects to initiate its Phase 1 trial evaluating IMM - 1-104 in 1H 2022. IMM - 1-104 is a highly selective dual - MEK inhibitor that has been designed to overcome MAPK - feedback loops and exhibits deep cyclic inhibition through its targeted potency and short half - life . As a result , Immuneering believes IMM - 1-104 has the potential to become an important new treatment option for advanced solid tumors in patients with a broad spectrum of mutations in genes , such as KRAS and NRAS , that activate the MAPK pathway . Third Quarter 2021 Financial Highlights • Cash Position : Cash and cash equivalents and marketable securities as of September 30 , 2021 were $ 159.6 million , compared with $ 37.1 million as of December 31 , 2020 .